A number of these mutations involve or bypass the MAPK pathway, and together with observations of tumor dedifferentiation after BRAF inhibitor therapy in cancer types such as melanoma [65, 66] and thyroid cancer [25, 67], we hypothesized that mechanisms that drive BRAF inhibitor resistance may overlap with that of anaplastic evolution. The gene discussed is BRAF; the disease is cancer.